Navigation Links
VIVUS Submits Qnexa(R) New Drug Application to the FDA for the Treatment of Obesity
Date:12/29/2009

erage baseline weight of 256 pounds; in CONQUER, the average baseline BMI of the study population was 36.6 kg/m(2) with an average baseline weight of 227 pounds. All patients were asked to follow a hypocaloric diet representing a 500-calorie/day deficit and advised to implement a simple lifestyle modification program.

About Qnexa

Qnexa (Q-NEX-uh) is an investigational drug being developed to address weight loss. Qnexa is a once-a-day, proprietary, oral, controlled-release formulation of low dose phentermine and topiramate, which is believed to address both appetite and satiety - the two main mechanisms that impact eating behavior - in one capsule. In phase 2 and 3 clinical studies, Qnexa has demonstrated significant weight loss, glycemic control, and improvement in cardiovascular risk factors.

About VIVUS

VIVUS is a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes and sexual health. The company's lead product in clinical development, Qnexa, has recently completed phase 3 clinical trials for the treatment of obesity and an NDA was submitted to the FDA in December 2009. Qnexa is currently in phase 2 clinical development for the treatment of type 2 diabetes. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a potentially best-in-class PDE5 inhibitor, and in phase 2 development of Luramist(TM) for the treatment of hypoactive sexual desire disorder (HSDD) in women. MUSE® (alprostadil), a first generation therapy for the treatment of ED, is already on the market and generating revenue for VIVUS. For more information about the company, please visit www.vivus.com.

Certain stateme
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Results From Phase 3 EQUATE Trial of VIVUS Qnexa Highlighted at European Congress on Obesity
2. VIVUS Initiates Open Label Safety Study of Avanafil for Erectile Dysfunction
3. Data on VIVUS Qnexa to be Featured at European Association for the Study of Diabetes Annual Meeting
4. VIVUS Announces Promotion of Peter Tam to President
5. VIVUS to Present at Lazard Capital Markets Healthcare Conference
6. VIVUS to Host Conference Call and Webcast Discussion of Avanafil Phase 3 Results
7. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
8. Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer
9. Vanda Pharmaceuticals Submits Iloperidone New Drug Application
10. Peregrine Pharmaceuticals Submits Clinical Protocol for New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
11. Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... , Dec. 18, 2014  RESMED INC. (NYSE: ... second quarter of fiscal year 2015 results on Thursday, January ... A press release with ResMed,s results will be issued after ... a webcast to discuss operating results and future outlook. ... p.m. US Pacific Time and the live webcast of the ...
(Date:12/19/2014)... Dec. 18, 2014   Aratana Therapeutics, Inc ... company focused on the licensing, development and commercialization ... positive results from its pivotal field study of ... pain in dogs with osteoarthritis.  In the study, ... scores that were statistically significant compared to placebo ...
(Date:12/17/2014)... DIEGO , Dec. 17, 2014 Royal ... Volcano Corporation (NASDAQ: VOLC ), a global leader ... announced that they have entered into a definitive merger agreement. ... to acquire all of the issued and outstanding shares of ... purchase price of USD 1 billion (approx. EUR 800 million), ...
Breaking Medicine Technology:ResMed To Announce Second Quarter 2015 Results 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 4Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 5Philips to acquire Volcano to expand global leadership position in image-guided therapy market 2Philips to acquire Volcano to expand global leadership position in image-guided therapy market 3Philips to acquire Volcano to expand global leadership position in image-guided therapy market 4Philips to acquire Volcano to expand global leadership position in image-guided therapy market 5Philips to acquire Volcano to expand global leadership position in image-guided therapy market 6Philips to acquire Volcano to expand global leadership position in image-guided therapy market 7Philips to acquire Volcano to expand global leadership position in image-guided therapy market 8
... Life Spine, a medical device company that designs, develops, ... spinal disorders, announced today amidst consolidations in the industry ... its history. As a full line spine company Life ... sacrum. Aileron™, a minimally invasive adjustable InterSpinous ...
... China, Nov. 4, 2011 /PRNewswire-Asia-FirstCall/ -- Mindray Medical International Limited ... marketer of medical devices worldwide, today announced that it will ... fair to be held between November 16 and 19 in ... H2 C07 at the 43rd World Forum of Medicine - ...
Cached Medicine Technology:Mindray Medical to Exhibit at MEDICA 2011 in Dusseldorf, Germany from November 16-19, 2011 2Mindray Medical to Exhibit at MEDICA 2011 in Dusseldorf, Germany from November 16-19, 2011 3
(Date:12/21/2014)... AngelWeddingDress.com’s new collection of 2015 spring ... of 1,000 new designs in this collection, and all ... , AngelWeddingDress.com promises to provide the most ... essentials while many fashion trends come and go. If ... team at AngelWeddingDress.com is ready to assist. , ...
(Date:12/21/2014)... HealthDay Reporter FRIDAY, Dec. 19, 2014 ... than traditional cigarettes, new research finds. Even though ... thousands of ex-smokers said they have fewer cravings and are ... to smoke, researchers reported. "The pattern was ... use than for tobacco use," said lead researcher Jonathan Foulds, ...
(Date:12/21/2014)... 2014 The number of Mirena lawsuits ... litigation underway in New Jersey, Bernstein Liebhard LLP reports. ... claims involving the birth control IUD have now been ... filed by women who allege spontaneous migration of the ... perforations and other complications they were inadequately warned about ...
(Date:12/21/2014)... 21, 2014 Serious Buyer, Andrew Hawley ... Jm Morrison and the Doors International Ballroom at the ... also be the only time that Morrison's mother would ... Nov. 25, 1967. According to Hawley, “This would be ... play the Alexandria Roller Rink earlier that year and ...
(Date:12/21/2014)... 21, 2014 Over the past 39 ... in hundreds of emergency departments across the nation, from ... have been translated into an innovative suite of tools, ... deficiencies and enhance the patient experience. , NES ... staffing and management services for hospitals, announced the development ...
Breaking Medicine News(10 mins):Health News:2015 Spring Wedding Dresses From AngelWeddingDress Just Released 2Health News:E-Cigarettes Less Addictive Than Regular Cigarettes, Study Finds 2Health News:E-Cigarettes Less Addictive Than Regular Cigarettes, Study Finds 3Health News:Mirena Lawsuits Approach 1,400 in Bergen County Litigation, Bernstein Liebhard LLP Reports 2Health News:Mirena Lawsuits Approach 1,400 in Bergen County Litigation, Bernstein Liebhard LLP Reports 3Health News:NES Health Launches Stipend Program for Emergency Physicians in Training to Financially Assist Emergency Department Doctors While They Learn 2
... WLAN provides Palmer with critical access control features and ... support for bandwidth-intensive applications, ... Conference -- Colubris Networks, the leading global provider of,intelligent ... that Palmer College of Chiropractic, the largest,chiropractic college in ...
... Late breaking results from the SPIRIT III trial, presented ... Cardiovascular Research Foundation, show that after 12 months, there ... as heart attacks, deaths from cardiac causes or repeat ... blockage after using a Xience V everolimus-eluting coronary stent ...
... at Baylor College of Medicine boosted its sequencing capabilities ... Sequencer FLX Systems from 454 Life Sciences, a Roche ... Human Genome Sequencing Center will be in a unique ... ranging from the deciphering of new genomes to the ...
... Oct. 23 Immunosyn,Corporation (OTC Bulletin Board: IMYN) has ... Chief Executive Officer, President and,board member. "I am ... and help,shape the company,s success. I believe we have ... of people who suffer from painful and,debilitating diseases," says ...
... small financial incentives to health workers in low-income countries may ... malaria in young children, according to a study published on ... by an expert panel as one of eight of the ... research and policy and will be presented at the launch ...
... 23 Mylan Inc. (NYSE: MYL ),today ... Inc. have,entered into a patent license and settlement ... Extended-release (ER),Tablets, the generic version of GSK,s Paxil ... Paroxetine HCl ER Tablets will be dismissed with,prejudice. ...
Cached Medicine News:Health News:Palmer College of Chiropractic Selects Colubris Networks to Provide Wireless Infrastructure at Three U.S. Campuses 2Health News:Palmer College of Chiropractic Selects Colubris Networks to Provide Wireless Infrastructure at Three U.S. Campuses 3Health News:Fewer adverse cardiac events at one year 2Health News:Baylor College of Medicine increases fleet of Roche Genome Sequencer FLX Systems to 10 instruments 2Health News:Immunosyn Corporation Names Stephen Ferrone as CEO 2Health News:Financial incentives may hold key to cutting child malaria deaths 2Health News:Mylan Announces Settlement of Paroxetine Hydrochloride Extended-Release Tablets with GlaxoSmithKline 2
Desmarres Lid Retractor thin solid blades. Size 2....
The Storz Protege is an anterior segment unit only....
... all the features of phaco systems costing ... minimal maintenance. Small, light and tough enough ... Lowest cost reusable tubing kit can be ... there a price objection to purchasing a ...
... The Horizon Phacoemulsification ... anterior segment surgical system. ... offers high-end performance and ... console. It also provides ...
Medicine Products: